Search Grants — Free, No Account Required

Hawaii State Foundation on Culture and the Arts (SFCA)

SFCA provides biennium grants to arts organizations across Hawaii for general operating support, arts programming, and cultural preservation, fostering Hawaii's diverse cultural heritage and creative communities.

Survivor Theatre Project

Healing Through Creative Arts Workshop Series & Performance

Survivor Theatre Project

Healing Through Creative Arts Workshop Series & Performance

Path with Art

Hear and Now will bring attention to issues surrounding homelessness. Hear and Now will bring adults living in or who are in recovery from homelessness, addiction or other trauma, together with members of the general public to conceptualize a response to community perceptions of homelessness through music and performing arts. Interactive exhibitions of the S'Leiterwägeli sound sculpture, community art classes, and performances will take place throughout 2019.

Cascade Neighborhood Council

The Cascade Neighborhood Council will organize a series of interactive public art events to celebrate the role of the arts and artists in the Cascade neighborhood. The events will be held November 1 and December 6, 2018 and January 3 and February 7, 2019. Each event will take place 5pm - 7pm. They will be held at Low Income Housing Institute - Lakeview Building located at 1170 Harrison St and other locations in the Cascade neighborhood.

NIAID - National Institute of Allergy and Infectious Diseases

Project Summary/Abstract HIV disease remains a considerable public health concern without a practicable cure. Drug-based therapy can control HIV but is costly, has severe side effects, and is not curative. Stem-cell based therapies have provided the only known cures for HIV infection, with only a handful of individuals functionally cured to date. However, replicating these successes has been challenging due to the high toxicities of treatment, need for transplant antigen matching, and require extensive myeloablation. However, these “cures” strongly suggest that immune system modification involving hematopoietic stem/progenitor cell (HSPC) transplantation can play a strong role allowing HIV clearance from the body. We aim to achieve a HIV-1 cure by enhancing and optimizing anti-HIV cellular immune responses through genetic modification of autologous Hematopoietic Stem/Progenitor Cells (HSPCs) with an anti-HIV Chimeric Antigen Receptor (CAR) molecule (CAR-HSPC). Unlike combined antiretroviral treatment (ART), which cannot eradicate HIV due to persistent reservoirs, our approach targets lifelong anti-HIV responses for HIV clearance. We will improve the engraftment of CAR-modified stem cells by using clinically relevant conditioning methods, maintain long-term progenitor phenotype in CAR stem cells for repopulation capability, and improve homing to the bone marrow. Additionally, we will characterize the differentiation and therapeutic effects of HSPC-derived CAR modified immune cells in various tissue reservoirs using humanized mouse models. We will develop an in vivo targeting regimen incorporating stem cell targeted nanocapsules encapsulating CAR lentivirus to generate CAR-modified stem cells in vivo and evaluate for feasibility and efficacy. Our proposed study will provide crucial insights for investigational new drug (IND) development of HSPC-based CAR immunotherapies, potentially leading to ART-free HIV suppression and a functional cure.

Majam Research

The fund will pay for a public seating area in the park and the slab portion of a feature made for grinding on at the River City Skate Park located at 736 S Cloverdale St Seattle WA 98108 in the South Park neighborhood. The anticipated project completion date is 2/28/2022.

NIGMS - National Institute of General Medical Sciences

The University of Louisville (UofL) Phase III Hepatobiology and Toxicology (H&T) COBRE is a unique thematic center focused on liver research. The UofL H&T COBRE concentrates on the mechanisms and therapeutic strategies for multiple forms of liver disease/injury, including: Metabolic dysfunction-associated steatotic liver disease—the most common liver disease in the US/worldwide, and is highly linked to the metabolic syndrome; Alcohol-associated Liver Disease—a common problem among those who drink; Environmental Toxicant Induced Liver Injury—an increasingly recognized problem, and Louisville has been a leader in this area; Hepatitis B and C—important causes of cirrhosis and hepatocellular carcinoma worldwide; Personalized Medicine—an increasingly important factor in medication efficacy, and most drugs are metabolized in the liver; and Drug-Induced Liver Injury—the most common reason drugs are removed from the market. This COBRE brings together experienced senior mentors/investigators and promising junior investigators to perform cross- cutting research on the unique topics of Hepatobiology and Toxicology that adversely impact the health of Kentuckians and Americans. We address critical barriers in our understanding of the development/ progression of liver disease and we define targets for prevention/treatment that could transform clinical practice. Specific Aims of the Phase III Hepatobiology and Toxicology COBRE are to: 1. Expand and strengthen a thematically-focused program in Hepatobiology and Toxicology created in Phase I/II that helps build and sustain the overall research infrastructure at UofL. 2. Solidify infrastructure through streamlined, sustainable cores that provide necessary research resources and translational science/basic technologies to support state-of-the-art research in Hepatobiology and Toxicology 3. Expand and strengthen both a pilot program in H&T that explores new concepts and approaches and a multidisciplinary program in mentoring and career development. 4. Discover new mechanisms/molecular targets and effective means for preventing and/or treating liver diseases/toxicant exposures and communicate our findings to the public. In summary, this Phase III application builds on a highly successful Phase I/II H&T COBRE that has and will continue to increase capacity and sustainability in a unique topic to the COBRE program. The problem of liver diseases and environmental toxicity is highly relevant to Kentuckians and a focus of the UofL Strategic Plan. Seven of nine graduated RPLs obtained R01-type funding and all have been promoted and remain in academics. All of our PPLs also obtained some type of NIH/external research funding. We have been national leaders in liver disease and environmental toxicity. We interact closely with other IDeA entities and NIH-funded centers at UofL. The University has and will continue to invest in this program. This Phase III will provide resources for building capacity, infrastructure and sustainability.

NIGMS - National Institute of General Medical Sciences

Project Summary / Abstract The University of Chicago Integrated Light Microscopy Facility (ILMF) requests funds to purchase a high-end laser scanning confocal microscope. The ILMF currently serves 420 users in 80 labs from across the University. Sixty-seven of those labs use laser scanning confocal microscopy, and 78% of those labs have NIH funding. Usage hours have increased as the ILMF’s microscope capacity has decreased. Two of our confocal microscopes, both Leica SP5 models, are over 14 years old. Leica has designated them end-of-life, meaning they are no longer manufacturing parts for these systems and replacements are not guaranteed. We have already experienced failure of the 488nm Argon and 592nm depletion lasers on one, and failure of the Mai Tai multiphoton excitation laser on the other, with no possibility of replacing any of these components. We expect to decommission at least one SP5 within the next year, making users hesitant to start new projects on those systems. This has stressed our two newer laser scanning confocal systems (purchased with institutional funds in 2016 and 2020), pushing them to use levels averaging 91% of AUT, defined as 3640 hours per year. The system proposed here is the Evident (formerly Olympus) Fluoview 4000 (FV4000), released in 2024. The system will increase the capacity and functionality of laser scanning confocal microscopes in the ILMF, allowing users to collect high-quality data more readily. Several features of the FV4000 will be new to the ILMF, and satisfy a number of outstanding investigator needs. Features include: state-of-the-art, patented, fast signal processing silicon photomultiplier (SiPM, Evident SilVIRTM) detectors, to significantly improve signal-to-noise levels, enhancing detection of Golgi cisternae and other organelle sub-structures; four high magnification, long working distance silicone immersion objectives for detailed, multi-color, 3-dimentional imaging of organoids, thick tissues and tumor samples; and three near-infrared wavelength lasers for excitation of fluorophores beyond the current imaging spectrum, allowing for investigation of a larger number of molecules of interest in a single sample. The FV4000 will also feature full environmental control, allowing users to take advantage of faster imaging speeds to image live samples. This will make it possible to image longer sessions at higher frame rates with less photodamage, resulting in more robust and reliable data from live samples than currently possible. Finally, the FV4000 base is modular in design, allowing for field upgrades with Evident or third-party resources (e.g. a single molecule localization module) as users’ experimental needs grow. In summary, adding an Evident FV4000 laser scanning confocal microscope to the ILMF will make it possible for users to gather information from samples that are currently challenging but valuable research models.

OD - NIH Office of the Director

Summary. We request funds to purchase a new 6-laser (320nm, 355nm, 405nm, 488nm, 561nm, 637nm), SONY ID7000E spectral flow cytometer to alleviate excessive demand for existing multi-parameter flow cytometers and to add additional spectral capability to the Core. The requested instrument will support the research of 16 major users and 32 minor users holding 78 NIH grants, as well as additional projects supported by the Department of Defense, private industry, and foundations. Our users are agitating for an additional instrument because their students, postdocs and technical staff are having difficulties booking appointments on the current (over-subscribed) instruments. In addition, they realize that the new spectral instruments have important features (like compensation for autofluorescence, enhanced small particle detection, and detection of a wider array of fluorochromes and fluorescent proteins) that are not possible on our current flow cytometers. Thus, the requested instrument will help users perform their funded and future experiments that require high- dimensional antibody panels, including users who use the immunophenotyping service for clinical samples. To meet these needs, we are requesting funds to purchase a new state-of-the-art, 6-laser Sony ID7000E spectral flow cytometer. The requested instrument will be administered by the FCSC Core and will be incorporated into the Core's existing financial plan. The FCSC Core is part of the UAB Institutional Research Core Program (IRCP) and receives significant institutional support from the IRCP on a yearly basis. The FCSC Core also receives yearly support from the UAB Cancer Center, the UAB Center for AIDS Research (CFAR) and the UAB Immunology Institute. These entities will also contribute $50,000 towards the purchase of the requested instrument. Five highly experienced flow cytometry specialists in the FCSC Core, each trained to operate the ID7000E, will be available to train new users in instrument operation and to assist them with the development of multi-parameter antibody panels. Finally, the FCSC Core is located in the Shelby Biomedical Research Building, which houses the research laboratories of many of our major users and is within a short walking distance of our other users on campus. Thus, the requested ID7000E instrument will add urgently needed capability and allow us to provide state-of-the-art instruments and services to our users in a timely manner.

OD - NIH Office of the Director

Health sciences research in the modern age has been revolutionized by automation and the high sensitivity of mass analysis provided by state-of-the-art quantitative mass spectrometry (MS) instruments. The Lumigen Instrument Center (LIC) at Wayne State University has a mission to provide researchers at the university and in the regional area with reliable user-based high throughput targeted MS analysis to elevate their research productivity. As part of the strategic plan of the Mass Spectrometry Laboratory in the LIC, the Mass Spectrometry Advisory Committee identified two current challenges for users. First, the number of targeted mass spectrometry analyses has drastically increased to over 13,000 analyses per year, which has dramatically affected user research productivity. Second, development of new methods to address the unique needs of individual users is limited due to the absence of new and powerful technologies, including high throughput automation and more sensitive triple quadrupole mass spectrometers. To address these challenges, this application requests funds for a high throughput solid phase extraction liquid chromatograph Mass Spectrometer (HT-SPE-LC-MSMS) at Wayne State University. The instrument will significantly enhance research accomplishment in mass spectrometry (MS) on our campus. First, the HT-SPE- LC-MSMS will increase the LIC's targeted mass spectrometry analysis rate. Second, the instrument will provide the only mass spectrometer in a shared facility on campus with high throughput, online solid phase extraction, targeted analysis capability, which will enable NIH-funded researchers to expand and transform their research activities and lower laboratory sample preparation costs. The multiple capabilities of the instrument will include cyanotoxin and cyanopeptides, mycotoxins, VOC metabolites, PFAS, hormones, endocrine disruptors, drugs of abuse, and ADME, API stability, and purity analyses. The instrument will support the research programs of at least 20 users at Wayne State University and the regional area, which include chemists, biologists, environmental scientists, and medical researchers. The HT-SPE-LC-MSMS will be housed and maintained in the LIC, which has strong institution support from the University, the Division of Research and Innovation, and the College of Liberal Arts and Science. The LIC has an exemplary record of instrument stewardship, with dedicated staff, facilities, and management to support the long-term use of the instrument. Importantly, the user-focused structure of the LIC will promote development of a unique array of new methods for each user's individual research projects. The acquisition of a HT-SPE-LC-MSMS is aligned with the long-term strategic plan of the Mass Spectrometry Facility at the LIC, which seeks to provide state-of-the-art and reliable MS instruments to implement innovative user-initiated projects at Wayne State University and local area community.

Multimedia Resources and Training Institute (MMRTI)

Multimedia Resources Training Institute will create a 1 hour documentary, 30 photo portraits, and other multimedia projects produced by youth interns.  They will focus on Seattle's Central Area, a Historic Arts and Cultural District. The project will empower youth to act as community advocates through photography and video.

New Britain Museum of American Art

Historic Restoration Fund

New Britain Museum of American Art

Historic Restoration Fund

National Endowment for the Humanities

HISTORIC ROCK FORD AMERICA 250 PUBLIC EDUCATION [HISTORIC ROCK FORD IS OWNED AND OPERATED BY THE ROCK FORD FOUNDATION, A NON-PROFIT ORGANIZATION. THE SITE CONSISTS OF THE POST-REVOLUTIONARY WAR HOME OF ADJUTANT GENERAL EDWARD HAND AND THE JOHN J. SNYDER JR. GALLERY OF EARLY LANCASTER COUNTY DECORATIVE ARTS AND WILL PLAY A PIVOTAL ROLE IN LANCASTER'S AMERICA250 CELEBRATION. AT THE HEART OF THAT CELEBRATION IS PUBLIC EDUCATION ABOUT THE REVOLUTION AND ITS CULTURAL CONTEXT. AS PART OF THE PUBLIC EDUCATION INITIATIVE IN 2026, THE ROCK FORD FOUNDATION WILL: 1. REPUBLISH AND UPDATE A SERIES OF NOW OUT-OF-PRINT PAMPHLETS ON LANCASTER COUNTY IN THE REVOLUTION, 2. HOST LECTURES, WORKSHOPS, AND LIVING HISTORY PRESENTATIONS, AND 3. HOST LARGE-SCALE LIVING HISTORY EVENT, CELEBRATE AMERICA 250 AT HISTORIC ROCK FORD, TO OFFICIALLY MARK THE ANNIVERSARY OF THE DECLARATION OF INDEPENDENCE IN JULY OF 2026.]

NIAID - National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY/ABSTRACT Cryptococcus neoformans is the most common disseminated fungal pathogen in people living with HIV/AIDS, causing an estimated quarter million cases of cryptococcal meningitis annually and resulting in over 180,000 deaths worldwide. In the United States alone, the annual economic burden of cryptococcal disease exceeds $535 million. Despite the availability of antiretroviral therapy (ART) and antifungal drugs, mortality rates remain unacceptably high, ranging from 10–30% in medically advanced settings to 30–50% in resource-limited regions. Current antifungal therapies are constrained by toxicity, limited drug classes, emerging resistance, medication shortages, and reliance on host immune function. Thus, there is a critical need to identify new fungal pathways and targets to support antifungal drug development. We identified that multiple HIV integrase strand transfer inhibitors (INSTIs), including bictegravir, dolutegravir, raltegravir, elvitegravir, and cabotegravir, exhibit anti- cryptococcal activity in vitro, indicating a class effect. This activity was observed across multiple strains of C. gattii and C. deneoformans, but not against other fungal pathogens, suggesting species-specific effects. In combination studies, INSTIs demonstrated additive or synergistic interactions with amphotericin B, flucytosine, and fluconazole. In a murine model of cryptococcal infection, elvitegravir treatment resulted in a modest but statistically significant reduction in fungal burden, and combination treatment with fluconazole further enhanced fungal clearance relative to fluconazole alone. To investigate the fungal targets underlying these effects, we employed a structure-based computational approach using Foldseek to identify cryptococcal proteins with tertiary structural similarity to HIV-1 integrase. This analysis identified an uncharacterized protein in C. deneoformans containing an RNase H–like domain derived from a retrotransposon-associated protein. Orthologs of this domain were identified in C. neoformans (CKF44_05263 and CKF44_07425), but not in Candida albicans or Aspergillus fumigatus, consistent with the observed species-specific antifungal activity. In parallel, a transcription factor deletion screen identified 4 TFs, Fzc40, Fzc5, Hlh3, and Rds2, that contribute to resistance against multiple INSTIs. The proposed studies will use complementary genetic, biochemical, and transcriptomic approaches to define the cryptococcal genes and pathways mediating sensitivity and resistance to INSTIs and to determine whether CKF44_05263 and/or CKF44_07425 function as INSTI-responsive targets. While INSTIs are not proposed as direct therapeutics for cryptococcosis, these studies leverage INSTIs as chemical probes to uncover novel, druggable fungal pathways. Successful completion of this work will advance fundamental understanding of cryptococcal biology and provide a foundation for the rational development of new antifungal agents, directly aligning with NIAID’s mission to support fundamental discoveries and innovative research strategies to protect and improve human health.

NIAID - National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY/ABSTRACT Despite the success of antiretroviral therapy (ART) in suppressing viral replication, no cure for HIV has been found. This is because HIV persists in a reservoir comprised of intact, inducible HIV proviruses in CD4+ T cells and, to a lesser degree, myeloid cells. A deeper, more quantitative understanding of the forces that sustain the reservoir will allow us to engineer more effective HIV cure therapeutics. We know that the HIV reservoir decays in the first ~7 years after ART initiation, but reservoir dynamics in the second decade and beyond are not well characterized. Of the few individuals studied longitudinally out to 20 years, some experience continued reservoir decay while others show signs of reservoir expansion. In this work, we will conduct a large, multi-decade, multi- platform study of the dynamics of latently infected cells and host CD4+ T cells. We will use this data to estimate the relative contributions of the biological factors that sustain the reservoir at different points in time after ART initiation. We will test the hypothesis that the reservoir initially decays due to immune selection, after which the reservoir’s persistence is largely driven by the kinetics of the most highly-expanded, infected clones. In the first aim, we will characterize 20-year HIV reservoir trajectories using the intact proviral DNA assay in dozens of people living with HIV (PWH) on ART and identify biological factors that differ between those with continued decay and those with expansion in the second decade on ART. Biological factors examined include expansion rates of underlying HIV-infected CD4s and uninfected memory CD4s, CMV serostatus, and sex. In the second aim, we will quantify the contribution of antigen-specific clonal proliferation to overall memory (m)CD4+ T cell persistence in a subset of PWH on long-term ART. To do this, we will first use the ViraFEST assay to identify T- cell receptor (TCR)β sequences of mCD4+ T cells that proliferate in response to one of four viral antigens. Then we will obtain longitudinal resting mCD4+ TCRβ and paired TCRαβ repertoires from the same individuals and track each antigen-specific clone’s proliferative kinetics over 20 years on ART. We will model these thousands of antigen-specific clone trajectories to provide insight into how antigen exposure shapes long-term persistence of memory CD4+ T cells. In the third aim, we will refine, validate, and extend our stochastic model of HIV reservoir dynamics to incorporate 20 years of ART data. First, we will generate empiric data on clone kinetics of CD4s harboring intact and defective proviruses and uninfected mCD4s by performing near-full length sequencing and mCD4+ TCR repertoire sequencing on longitudinal samples. We will use this data to refine and validate our current model and extend its applicability to the first twenty years on ART, thus providing a comprehensive framework to estimate the relative contributions of various forces, such as immune selection and antigen-driven proliferation, in driving reservoir dynamics at different times after ART initiation. Our study will yield quantitative insight that will be immediately applicable to HIV cure efforts and will generate a freely available, advanced mathematical model of the reservoir that can provide predictions to optimize the design of future HIV cure trials.

NIAID - National Institute of Allergy and Infectious Diseases

Project Summary HIV drug resistance represents a growing and underappreciated threat to the U.S. HIV response. Although more than 1.2 million people are living with HIV in the U.S., only about 60% achieve durable viral suppression, and resistance is a major contributor to treatment failure and regimen switching. Current resistance testing relies on centralized, PCR and sequencing-based platforms that are expensive, slow, and available only at specialty laboratories, requiring multiple clinic visits and highly trained personnel. As a result, same- day, resistance-informed treatment decisions are rarely possible, even in major U.S. cities, and are essentially inaccessible in rural areas, mobile care units, and safety-net clinics serving areas where the epidemic is increasingly concentrated. These gaps most severely affect communities already carrying the highest burden of HIV incidence and treatment failure in the U.S. Without affordable, accessible, point-of-care (POC) resistance testing, the durability of ART and the success of the national Ending the HIV Epidemic initiative are at risk. Our project aims to develop HIV-CRISP to addresses this critical gap by developing a cost-effective, same- visit “test-and-switch” POC device that integrates CRISPR-based nucleic acid detection with a bioinspired microfluidic chip (CamoChip). This fully automated platform enables simultaneous detection of HIV viral load and drug resistance to four major ART classes (NRTIs, NNRTIs, INSTIs, and PIs) during a single clinic visit. By empowering providers to make immediate, resistance-informed treatment decisions, HIV-CRISP reduces delays in therapy initiation or modification and minimizes the risk of treatment failure. The project is structured around three specific aims: Specific Aim 1: optimize a PAMmer-assisted CRISPR system for accurate detection and profiling of HIV drug resistance mutations; Specific Aim 2: enhance CamoChip readout technology for rapid, multiplex POC testing; and Specific Aim 3: integrate these components into a user-informed POC device and validate its performance against standard methods with clinical samples. Each aim not only drives independent scientific advances but also converges on the development of a transformative POC diagnostic. HIV-CRISP represents an innovation in HIV diagnostics with broad public health significance. This platform supports wide access to high-quality HIV care in under-resourced settings across the U.S. and globally, while also providing a foundation adaptable to other infectious diseases and health conditions.

NIMH - National Institute of Mental Health

Despite the widespread use of antiretroviral therapy (ART), it is estimated that up to 50% of people living with HIV (PLWH) experience HIV-associated neurocognitive disorders (HAND). HAND decreases quality of life but critically, progression to more severe forms like HIV-associated dementia (HAD) often occurs, especially with increasing age. Associations between neuroinflammation and HAND are known to exist, but the molecular mechanisms driving this are poorly understood. Recently, it has been established that previous inflammatory insults can alter the response of innate immune cells to subsequent inflammatory stimuli, a concept termed innate immune memory (IIM). Trained immunity (TI) is an IIM phenotype classified by hyperresponsiveness to secondary stimulation and is established through epigenetic and metabolic reprogramming. TI is protective in the context of repeated acute insults, but maladaptive in chronic disease. Multiple published studies have suggested that TI occurs in peripheral myeloid cells of PLWH, but whether this occurs in microglia remains unexplored. Preliminary data in the C20 microglial cell line has suggested exposure to HIV-1 induces TI. In addition, multiple reported microglia gene expression signatures in the context of HIV-1 align with trained microglia signatures in other contexts. If TI is established in microglia of PLWH, the characteristic hyperresponsiveness to inflammatory insult could exacerbate neuroinflammation, driving establishment or progression of HAND. Further, TI-like epigenetic reprogramming is known to persist despite cure from other diseases of viral etiology such as hepatitis C virus (HCV), where “epigenetic scarring” drives persistent chronic inflammation and increased liver cancer risk despite virus eradication. Similarly, chronic neuroinflammation and HAND could persist despite HIV cure due to long-lived microglia remaining in the trained state. This possibility, along with the implications of TI in HAND pathogenesis, warrants scientific inquiry into the mechanisms and functional outcomes of HIV-1-induced TI in microglia. In Aim 1, a novel in vitro TI model will be established in human monocyte-derived microglia (MDMi), solving the long- standing issue of lacking physiologically relevant models in the broader microglia TI field. Using this model, HIV- derived molecular inducers of TI will be identified, and epigenetic and metabolic mechanisms of HIV-induced TI will be elucidated utilizing chromatin immunoprecipitation (ChIP) and Seahorse metabolic assays. In Aim 2, the functional outcomes of HIV-1 induced TI will be explored through investigation of perturbations in phagocytic capacity, ROS production, iNOS activity, and microglia morphology. Further, RNA-sequencing will generate transcriptomic signatures of HIV-trained microglia, aiding in elucidation of therapeutic targets and identification of biomarkers for HIV-trained microglia. The proposed fellowship training plan integrates advanced technical training with professional development, leadership, and career preparation. Research will be conducted in an environment that offers extensive expertise in neuroHIV, access to state-of-the-art core facilities, and a collaborative, interdisciplinary culture that supports both rigorous science and trainee development.

National Institutes of Health

<p>The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting four Clinical Trials Networks (CTNs) each comprised of a Leadership and Operations Center, Statistical and Data Management Center, and Laboratory Center (LC) working with Clinical Trials Units, to&nbsp;test&nbsp;prevention and treatment&nbsp;strategies and conduct implementation research designed to end the HIV epidemic. This NOFO will solicit applications for up to four LCs that will provide laboratory structure and technologies to one or more CTNs and conduct laboratory testing for Network trials, according to regulatory standards. The LC oversees site-affiliated clinical and specialized laboratories and ensures protocol-specified laboratory testing.&nbsp; The LC will: 1) support sample integrity from collection to final testing/storage; 2) use appropriate laboratory data capturing management and tracking systems; 3) select, determine readiness, and approve laboratories; and 4) promote state-of-the-art laboratory assays.&nbsp;The LC will increase testing capacity to meet advances in prevention and treatment of HIV and HIV-related diseases.</p><p><br>Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.</p>

National Institutes of Health

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting four Clinical Trials Networks (CTNs) each comprised of a Leadership and Operations Center, Statistical and Data Management Center, and Laboratory Center (LC) working with Clinical Trials Units, to test prevention and treatment strategies and conduct implementation research designed to end the HIV epidemic. This NOFO will solicit applications for up to four LCs that will provide laboratory structure and technologies to one or more CTNs and conduct laboratory testing for Network trials, according to regulatory standards. The LC oversees site-affiliated clinical and specialized laboratories and ensures protocol-specified laboratory testing. The LC will: 1) support sample integrity from collection to final testing/storage; 2) use appropriate laboratory data capturing management and tracking systems; 3) select, determine readiness, and approve laboratories; and 4) promote state-of-the-art laboratory assays. The LC will increase testing capacity to meet advances in prevention and treatment of HIV and HIV-related diseases.Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

Community Art Center

Home Port

Community Art Center

Home Port

Hong Kong Jockey Club Charities Trust

One of the world's top charity donors (500M+ USD/yr). Supports youth, elderly, sports, arts, and community programs in Hong Kong.